Merrill maintains Human Genome at neutral

Human Genome Sciences, Inc. was maintained by Merrill Lynch analyst Hari Sambasivam at a neutral rating after the company said it is planning to advance Lymphostat-B to phase 3 trials this year. The primary indication will be lupus. Albuferon could enter phase 3 trials before the end of the year pending interim 12-week phase 2 data for Albuferon plus ribavirin in the first quarter of 2006 in therapy-naive patients. The company also said it received a $5 million milestone payment from GlaxoSmithKline for GSK716155 for type 2 diabetes. Shares of the Rockville, Md., biopharmaceutical company were down 12 cents, or 1.17%, at $10.15 on volume of 3,295,761 shares versus the three-month running average of 2,998,670 shares. (Nasdaq: HGSI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.